World's Best Scientists 2026 revealed!
Markolf Hanefeld

Markolf Hanefeld

D-Index & Metrics

Medicine

D-Index
85
Citations
37846
World Ranking
14398
National Ranking
763

Overview

Markolf Hanefeld is a researcher affiliated with TU Dresden in Germany, primarily working in the field of medicine with a focus on endocrinology, diabetes, and metabolism. Their research encompasses topics such as diabetes treatment and management, pharmacology and obesity treatment, metabolism in connection to diabetes and cancer, hormonal and reproductive studies, diabetes management and research, lipoproteins and cardiovascular health, and neuropeptides and animal physiology.

Hanefeld has contributed to several recent publications, including:

  • The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial, 2020, published in The Lancet Diabetes & Endocrinology
  • The Current and Potential Therapeutic Use of Metformin-The Good Old Drug, 2021, published in Pharmaceuticals
  • Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study, 2020, published in Diabetes Obesity and Metabolism
  • Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update, 2020, published in Diabetes Therapy
  • Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial, 2021, published in The Lancet Diabetes & Endocrinology

Their frequent coauthors include Andreas L. Birkenfeld, Hertzel C. Gerstein, Helen M. Colhoun, Mark Lakshmanan, and Jeffrey L. Probstfield.

Hanefeld has published multiple works in venues such as:

  • The Lancet Diabetes & Endocrinology
  • Diabetologie und Stoffwechsel
  • Pharmaceuticals
  • Diabetes Obesity and Metabolism
  • Diabetes Therapy

The researcher's work spans several subfields, including pharmacology and surgery, and incorporates elements of molecular biology and cardiology. Overall, Markolf Hanefeld's body of work centers predominantly around diabetes and its treatment modalities, with a multidisciplinary approach linking metabolic processes and cardiovascular as well as hormonal functions.

Best Publications

  • Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

    Jean-Louis Chiasson;Robert G Josse;Ramon Gomis;Markolf Hanefeld

  • Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

    Jean-Louis Chiasson;Robert G. Josse;Ramon Gomis;Markolf Hanefeld

  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

    rosiglitazone Medication Trial Investigators;H C Gerstein;S Yusuf

  • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Paula S. Curtis

  • Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

    M. Hanefeld;S. Fischer;U. Julius;J. Schulze

  • Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Ramón Gomis

  • Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

    M. Hanefeld;M. Cagatay;T. Petrowitsch;D. Neuser

  • Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.

    Theodora S. Temelkova-Kurktschiev;Carsta Koehler;Elena Henkel;Wolfgang Leonhardt

  • Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

    D Ziegler;M Hanefeld;K J Ruhnau;H Hasche

  • Postprandial Glucose Regulation and Diabetic Complications

    Antonio Ceriello;Markolf Hanefeld;Lawrence Leiter;Louis Monnier

  • Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

    David Russell-Jones;Robert M. Cuddihy;Markolf Hanefeld;Ajay Kumar

  • Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

    G. Schernthaner;D. R. Matthews;B. Charbonnel;M. Hanefeld

  • Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance

    Markolf Hanefeld;Jean Louis Chiasson;Carsta Koehler;Elena Henkel

  • In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

    Frank Pistrosch;Jens Passauer;Sabine Fischer;Katja Fuecker

  • One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Markolf Hanefeld;Paolo Brunetti;Guntram H Schernthaner;David R Matthews

  • Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study

    Markolf Hanefeld;Carsta Koehler;Katja Fuecker;Elena Henkel

  • The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

    Emile R. Mohler;Christie M. Ballantyne;Michael H. Davidson;Markolf Hanefeld

  • Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.

    M. Hanefeld;C. Koehler;F. Schaper;K. Fuecker

  • Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

    Michel Komajda;John J.V. McMurray;Henning Beck-Nielsen;Ramon Gomis

  • Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance

    Jean-Louis Chiasson;Robert G. Josse;Markolf Hanefeld;Markku Laakso

Frequent Co-Authors

Patrick A. Ott
Patrick A. Ott Harvard University
Hertzel C. Gerstein
Hertzel C. Gerstein McMaster University
Antonio Ceriello
Antonio Ceriello MultiMedica
David R. Owens
David R. Owens Cardiff University
Guntram Schernthaner
Guntram Schernthaner Medical University of Vienna
Henning Beck-Nielsen
Henning Beck-Nielsen Odense University Hospital
Stuart J. Pocock
Stuart J. Pocock London School of Hygiene & Tropical Medicine
Philip Home
Philip Home Newcastle University
Markku Laakso
Markku Laakso University of Eastern Finland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a wide range of alternative online degrees and career pathways for those interested in healthcare, beyond becoming a physician. Many prospective students are drawn to direct entry msn programs, which allow those without a nursing background to earn a Master of Science in Nursing, opening doors to advanced practice roles in less time.

For those starting their journey, online adn programs for non nurses provide a fast and flexible pathway to become a registered nurse, with accessible admission requirements and a shorter timeline compared to traditional routes.

Not everyone in healthcare works on the frontlines. Administrative roles, such as medical coder or biller, are crucial and in demand. Many institutions offer medical coding and billing classes online with financial aid, making it easier to break into the field without incurring significant debt.

Admission testing can be a barrier for some. Fortunately, several schools do not require applicants to sit for exams like the TEAS or HESI. If you're wondering, do you have to take the teas test to get into nursing school, you'll find options that waive these requirements—making nursing education more accessible.

Best Scientists Citing Markolf Hanefeld

Trending Scientists

Recently Published Articles